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The adult skeleton is constantly renewed through bone remodeling. Four recent papers (Baldock et al., 2007;
Lee et al., 2007; Lundberg et al., 2007; Sato et al., 2007) provide new insights into central and peripheral con-
trol of this remodeling sequence. Two of the studies add to our knowledge of the complex hypothalamicmod-
ulation of bone turnover mediated by NMU and NPY via the sympathetic nervous system, while the other two
focus on the peripheral neural target, the osteoblast, and its regulation by neuropeptides and osteocalcin.
These findings support a new paradigm concerning the regulation of bone remodeling and provide a founda-
tion for novel approaches to preventing osteoporosis.Bone remodeling is a continuous process of skeletal renewal
during which bone formation is tightly coupled to bone resorp-
tion. Skeletal turnover is essential for maintaining bone strength,
regulating calcium homeostasis, and repairing microdamage
incurred by normal weight-bearing activities. Bone remodeling
also provides a framework for mobilizing calcium during excep-
tional physiological states. For example, calcium demands dur-
ing lactation are intense, yet the skeleton can readily meet those
needs by temporarily unbalancing the remodeling unit in favor of
resorption. In contrast, cessation of lactation leads to a relatively
rapid recovery of bone mass through enhanced bone formation
and suppressed bone resorption.
Skeletal remodeling requires a significant amount of energy for
the recruitment of osteoblasts and the deposition of collagen
matrix. But precisely how bone turnover is coupled to energy
metabolism was not clear until the turn of this century. In 2000,
Ducy and colleagues (2000) made the seminal observation that
hypogonadal ob/ob mice paradoxically exhibited very high
bone mass. Subsequently, the Karsenty/Ducy laboratory dem-
onstrated that leptin causes bone loss by activation of the sym-
pathetic nervous system (SNS) rather than through circulating
hormones or cytokines (Takeda et al., 2002). Identification of
the b2-adrenergic receptor (b2-AR) as the target for sympathetic
regulation of osteoblasts established a central regulatory loop
(Takeda et al., 2002; Elefteriou et al., 2005). Fu et al. then identi-
fied a series of ‘‘clock’’ genes as prime osteoblastic targets for
sympathetic activation by leptin (Fu et al., 2005; Karsenty,
2006).Within the past year, several new studies have further clar-
ified the relationship between skeletal remodeling and the cen-
tral nervous system (CNS).
In order to appreciate the significance of these recent findings,
it is helpful to conceptualize the interaction between bone and
brain as a regulatory unit composed of four phases (see Figure 1).
For the skeleton to sense fuel status, afferent signals from fat
storage depots are relayed to the hypothalamus (phase 1). In
the ventromedial nucleus of the hypothalamus (VMH), complex
neural processing occurs in conjunction with other neuronal cir-
cuits (phase 2). Glutamatergic, serotonergic, cannabinoid, and
NPY-ergic pathwaysmay also be activated by these afferent sig-nals. In phase 3, efferent output through the SNS targets the b2
receptor on theosteoblast. Themolecular pathwaysdownstream
of this activation include transcriptional, posttranslational, and
chromatin regulation of clock genes that regulate osteoblast pro-
liferation indirectly by inhibiting c-myc. This leads to suppression
of cyclinD1, a critical cell-cycle protein. Alternatively, b2 receptor
activation increases expression of the transcription factor AP-1 in
osteoblasts, which stimulates c-myc activity, illustrating a puta-
tive ‘‘checks and balances’’ system for neural regulation of oste-
oblasts (Fu et al., 2005). Lee et al. (2007) recently demonstrated
that osteoblasts can modulate adiponectin expression in adipo-
cytes, completing the regulatory loop between bone and brain
(phase 4). Four recent papers lend insight into three of the four
phases: phase 2 (Baldock et al., 2007; Lundberg et al., 2007),
phase 3 (Sato et al., 2007), and phase 4 (Lee et al., 2007).
In phase 1, fat cells control metabolic function by storing or
releasing energy in response to nutrient intake. Adipocytes
also synthesize cytokines, hormones, and growth factors that
modulate the activity of other cells. Shortly after its cloning and
identification, leptin emerged as a prime candidate for the energy
sensor of adipocytes. It is a prototypic adipokine, exhibiting clas-
sic endocrine activity by crossing the blood-brain barrier, en-
hancing reproductive status, and reducing appetite via the arcu-
ate nucleus (Spiegelman and Flier, 2001). Elegant studies have
established that leptin regulates bone remodeling through the
SNS by a relay in the VMH (Ducy et al., 2000; Takeda et al., 2002).
Adipocytes in the marrow can also secrete leptin, and there-
fore it is conceivable that leptin could influence adjacent stromal
cells to enter the osteoblast lineage. However, the importance of
this direct effect has been called into question because targeted
overexpression of leptin in bone does not produce a skeletal
phenotype (Astudillo et al., 2007; Takeda et al., 2002). Other adi-
pokines, such as adiponectin, promote insulin sensitivity and en-
hance osteoblastic proliferation but do not regulate sympathetic
activity (Berner et al., 2004). Fat cells synthesize other neuropep-
tides, such as PYY, that bind to peripheral Y receptors in osteo-
blasts. But leptin remains the primary energy sensor in fat tissue,
regulating hypothalamic efferent output to the skeleton in aman-
ner similar to its effects on appetite centers in the brain.
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MinireviewFigure 1. Central Regulation of Bone
Remodeling
Central regulation of bone remodeling occurs
through the hypothalamus but is determined by
both afferent and efferent signaling. Phase 1 is
the afferent leptin signal that originates from
peripheral adipocytes. Phase 2 involves the pro-
cessing of this signal in the hypothalamus, which
occurs in the ventromedial hypothalamus (VMH).
The mediators of this phase likely include neuro-
peptide Y (NPY) and neuromedin U (NMU). Phase
3 represents the efferent (sympathetic) output
from the hypothalamus to the b2-adrenergic re-
ceptor (b2-AR) on osteoblasts and the resultant
change in transcription factors and clock genes
that affect osteoblastogenesis. Suppression of os-
teoclastogenesis can occur indirectly through the
suppression of receptor activator of NF-kB ligand
(RANKL) in osteoblasts by cocaine- and amphet-
amine-regulated transcript (CART). NMUmay me-
diate its effects downstream of b2-AR on the clock
genes. Phase 4 represents skeletal regulation of
adipocytes, most likely through the systemic
release of osteocalcin. The dotted line in phase 4
represents the theoretical possibility that adipo-
cytes could regulate osteoblast proliferation and
differentiation. Other abbreviations: Y1, NPY
receptor 1; Y2, NPY receptor 2; NMUR, neurome-
din U receptor 2; OB, osteoblast; OC, osteoclast.Central control of appetite, reproduction, and bone remodel-
ing (phase 2) is a complex process, but progress in understand-
ing it has been evident. Previously, it had been shown that
chemical sectioning of the VMH with gold thioglucose replicates
the high bonemass and bone formation phenotypes of the ob/ob
mouse (Karsenty, 2006). Similarly, intracerebroventricular (i.c.v.)
leptin infusions to ob/obmice with their arcuate nuclei sectioned
by monosodium glutamate corrected the bone mass but did not
change body weight, suggesting distinct sites for regulation of
remodeling and appetite (Takeda et al., 2002).
Melanocortin, part of a family of peptides produced by post-
translational processing of pro-opiomelanocortin (POMC), had
originally been considered to be the major signaling molecule
mediating bone turnover. Two receptors for melanocortin are
present in the arcuate nucleus, and gene deletion of one leads
to mice with high bone mass and suppressed bone resorption
(Elefteriou et al., 2005). Mice with the melanocortin receptor
(MC4R) deletion show increased levels of another neuropeptide,
CART (cocaine- and amphetamine-regulated transcript), which
is also expressed in the arcuate nucleus and is regulated by lep-
tin (Ahn et al., 2006). Interestingly, CART suppresses expression
of receptor activator of NF-kB ligand (RANKL), which is
produced by osteoblasts and is essential for osteoclast differen-
tiation (Ahn et al., 2006). In the ob/ob mouse, bone formation is
increased, as is bone resorption, and CART expression in these
mice is absent in the hypothalamus. However, CART-deficient
macrophages and stromal cells differentiate normally, and there
are neither CART receptors nor evidence for CART expression in
bone, suggesting the presence of other central mediators of
bone turnover (Ducy et al., 2000; Elefteriou et al., 2005).
Neuropeptide Y (NPY) has been the focus of recent work by
the Herzog group. NPY belongs to a class of peptides including
PP and PYY that are expressed in the central and peripheral
nervous systems as well as in the gut. They signal through five
distinct receptors (Y1, Y2, Y4, Y5, and Y6) expressed in various
8 Cell Metabolism 7, January 2008 ª2008 Elsevier Inc.tissues. Like melanocortin and CART, NPY is synthesized in the
arcuate nucleus and increases appetite when overexpressed.
NPY-immunoreactive fibers have been identified within bone
marrow and the periosteum and preferentially around vascular
elements that surround marrow cells. Moreover, NPY treatment
of wild-type osteoblasts in vitro reduces cell proliferation. Previ-
ously, it was shown that mice with either a germline or hypotha-
lamic deletion of the Y2 receptor had increased cancellous and
cortical bone mass as well as greater bone formation, albeit no
change in bone resorption. Recently, Baldock et al. (2007) per-
formed germline deletion of Y1 receptors in mice and found
that these mice had high bone mass; however, when they per-
formed targeted deletion of Y1 genes only in the hypothalamus,
bone density was not altered. In an accompanying paper pub-
lished by the same group, marrow stromal cell proliferation
was greatly enhanced in the germline Y2/ mice, and this was
accompanied by in vitro evidence of increased mineralization
(Lundberg et al., 2007). Surprisingly, these mice had virtually
no Y1 receptors in bone cells. Taken together, data from these
two studies suggest that central NPY signaling may modulate
bone remodeling but that the anabolic effect of the Y2 gene
deletion is mediated by peripheral regulation of the Y1 receptor
on osteoblasts. Whether this occurs through NPY-ergic path-
ways emanating from the hypothalamus or through other central
pathways has yet to be determined.
One interesting sidelight to the Y2 null studies by Lundberg
et al. (2007) was the observation that marrow stromal cells
from the mutants more readily differentiated into adipocytes un-
der the appropriate culture conditions than wild-type cells did,
even though themutantmice had a lean phenotype with reduced
white adipose tissue and relatively fewer marrow adipocytes
than controls. The most likely explanation for this finding is that
in vitro studies do not reflect in vivo circumstances. However,
these data might be interpreted as indicating that marrow stro-
mal cells from Y2/ mice are more pluripotent than wild-type
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tween adipocytes and osteoblasts, it is conceivable that some
stromal cells could become adipocytes in order to provide
a source of energy for sustaining stromal cell differentiation
into osteoblasts. An example of the coexistence of marrow adi-
pogenesis and osteoblastogenesis is found in Ebf1 (early B cell
factor 1) null mice. These mice, on a mixed genetic background,
have markedly increased bone formation and high bone mass,
even though their bone marrow has an overabundance of adipo-
cytes (Horowitz and Lorenzo, 2007).
Phase 3 represents the efferent output of sympathetic activity
from hypothalamic signals to the osteoblast. How is this accom-
plished? Another recent study (Sato et al., 2007) provides insight
into this critical question. Neuromedin U (NMU) is a neuropeptide
produced by nerve cells in the brain, including the dorsomedial
nucleus of the hypothalamus and the pituitary, and in the submu-
cosal and myenteric plexuses of the small intestine. It binds to
NMU receptor 2 (NMUR2) in the hypothalamus and, like other
neuropeptides, can regulate appetite control and sympathetic
activation. In ob/ob mice, NMU is deficient but is corrected by
leptin treatment. Sato et al. studied NMU/ mice and found
high bone mass with increased bone formation, although iso-
lated osteoblasts and osteoclasts proliferated and differentiated
normally. These data implied that NMUmust act centrally to con-
trol remodeling. However, i.c.v. leptin infusion or b-adrenergic
agonist administration to NMU/ mice did not reduce bone
mass, suggesting that NMUmay actually be downstream of lep-
tin and the SNS. Indeed, Sato et al. also reported that central lep-
tin administration paradoxically increases osteoblast numbers in
NMU/ mice. These findings, along with the discovery that
NMU/ mice have high levels of the urinary catecholamine
metanephrine but increased bone mass and normal bone
resorption, imply either that the absence of NMU leads to skele-
tal resistance to sympathetic activation by leptin or that a com-
pensatory change occurs in other neuropeptides, thereby
balancing any increase in sympathetic tone. Interestingly,
CART expression was increased in the NMU/ mice, implying
that there must be a fine balance between the suppressive
effects of CART on osteoclastogenesis and the bone-resorbing
activity induced by sympathetic activation.
Why was bone formation enhanced in these mice if NMU/
osteoblasts and osteoclasts proliferate and differentiate nor-
mally in vitro? Sato et al. found one clue in the clock genes
Per1 and Per2, whose expression was significantly downregu-
lated in the NMU null mice. This finding was reminiscent of oste-
oblasts from the ob/ob mice, in which absence of b2-AR
signaling due to leptin deficiency causes reduced clock gene
expression and a subsequent increase in bone formation. How-
ever, there are limitations when comparing in vitro data with
in vivo data. Therefore, the exact mechanism causing the high
bone-mass phenotype in the NMU/mice remains to be deter-
mined.
A key to understanding central modulation of peripheral
remodeling are the clock genes, which encode a family of
proteins expressed in a circadian pattern. Type I collagen and
osteocalcin exhibit significant periodicity during a 24-hour cycle,
as do osteoprotegerin (OPG, an endogenous inhibitor of RANKL)
and parathyroid hormone (Gundberg et al., 1985; Joseph et al.,
2007). Interestingly, adipokines, including leptin, adiponectin,and resistin, also show circadian rhythmicity (Kalsbeek et al.,
2007). The master clock generator is located in the suprachias-
matic nucleus (SCN) of the hypothalamus. It entrains environ-
mental cues, such as light (via retinal neurons), feeding activity,
and hormonal signals, to regulate peripheral clock genes
through neuronal signals. At themolecular level, the clock engine
is characterized by two transcription factors, Bmal1 and Clock.
These proteins heterodimerize to regulate the expression of sev-
eral other circadian genes such as the periods (Per1 and 2), the
cryptochromes (Cry1 and 2), Rev-erba, Rora, and nocturnin. To
complete this regulatory loop, Per and Cry form a complex that
negatively feeds back on Bmal1 and Clock. Gene deletion of
Per 1 and 2 or Cry 1 and 2 results in mice with a high bone-
mass phenotype but withoutmajor changes in body composition
or other overt metabolic disturbances (Fu et al., 2005). Addition-
ally, these null mice have normal serum leptin levels, and sympa-
thetic activation is intact. This implies that themolecular clock for
regulating osteoblast-specific genes is downstream of b2-AR
and is an important mediator of phase 3 in the central control
pathway (Figure 1). Interestingly, in contrast to deletion of other
clock genes, mice with global knockout of nocturnin have
a body composition phenotype that includes leanness with en-
hanced insulin sensitivity and reduced periodicity of the Pparg
gene in response to high-fat feeding (Green et al., 2007). Skeletal
phenotyping of these mice should provide further insight into the
downstream effects of this clock gene on bone mass and body
composition.
In phase 4, osteoblasts regulate adipocyte function through
secretion of one or more mediators. If adipocytes can sense
energy and relay this to a central control network for fine tuning
bone remodeling, can the skeleton regulate fuel status in a sys-
temic manner? Lee and colleagues (2007) have now convinc-
ingly demonstrated that a soluble factor produced from fully dif-
ferentiated osteoblasts, but not fibroblasts, enhances insulin
signaling when islet cells are cocultured with bone cells. Just
as importantly, if adipocytes are cocultured with mature osteo-
blasts, adiponectin expression in the adipocytes is also mark-
edly increased. Based on earlier mouse and human studies,
Lee et al. hypothesized that osteocalcin was the soluble media-
tor responsible for influencing adipocytes and islet cells. To test
this hypothesis, they crossed mice with one allele of the osteo-
calcin gene deleted with mice that were deficient in Esp (Ptprv),
a protein tyrosine phosphatase expressed in Sertoli cells and
osteoblasts. Esp/ mice have profound hypoglycemia and
increased insulin sensitivity, but as a result of removal of one
copy of the osteocalcin gene, the hypoglycemic phenotype is
ameliorated. Furthermore, Lee et al. demonstrated that the
uncarboxylated form of osteocalcin is the most likely systemic
stimulator of insulin secretion. The implications of this landmark
paper cannot be overstated: for the first time, there is evidence
that the skeleton can actively regulate energy metabolism.
Clearly, more work needs to be done to define the target recep-
tor on islet cells and adipocytes for osteocalcin and to determine
the significance of the uncarboxylated form of this peptide ‘‘hor-
mone.’’ But functional linkage between bone and fat has been
established.
Although there is now incontrovertible evidence for the neural
control of bone remodeling, it is worthwhile to consider the impli-
cations of these new findings. There are a number of clinical
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ing to altered energy utilization and changes in bone mass. For
example, patients with Cushing’s disease or individuals with
severe depression have high serum cortisol levels, reduced
bone formation, fat redistribution, and a disruption in circadian
rhythms. Interestingly, a similar phenotype is seen in individuals
with chronic opioid addiction and patients with schizoaffective
disorders treated with newer agents such as olanzapine. If these
conditions represent a resetting in hypothalamic control of bone
remodeling, how are the efferent sympathetic signals to the skel-
eton sensed, and do these changes affect the clock genes of the
osteoblast? Also, are other neural pathways, such as those in the
dopaminergic and serotonergic systems, modulating bone turn-
over in these conditions? There is preliminary evidence suggest-
ing that serotonin is important in the central control of remodeling
and that gene deletion of the major serotonin receptor in osteo-
blasts, 5HT2BR, results in low bone mass and impaired
osteoblast proliferation (Collet et al., 2007). In the same light,
osteoblasts express both cannabinoid (CB1 and 2) and opiod
(mu) receptors. Agonists of CB2 have been shown to increase
bonemass, while deletion of the centralCB1 receptor gene leads
to high bone mass, probably as a result of impaired sympathetic
activation (Ofek et al., 2006). The recurring theme, that bone cells
express receptors for numerous neuropeptides, reinforces the
thesis that the CNS is a critical modulator of bone turnover.
These studies also raise new questions about the function of
marrow adipocytes relative to neighboring osteoblasts. Marrow
fat in adults can be measured by MRI and is now considered
a risk factor for low bone mass and fractures (Shen et al.,
2007). Age-relatedmarrow adipositymay be due to a compensa-
tory or default mechanism whereby marrow fat fills space previ-
ously occupied by bone, presumably because mesenchymal
stem cells enter the adipocyte lineage rather than the osteoblast
differentiation scheme. But it is also conceivable that marrow
adipogenesis may be dynamic, adapting to energy needs and
shifting its function depending on a particular environmental
condition in themarrow niche. For example, in anorexia nervosa,
despite the absence of peripheral fat, the marrow has an over-
abundance of adipocytes (Abella et al., 2002). Is this a response
to impaired bone formation from a central mechanism, or is this
an evolutionary response to protect the skeleton and maintain
function in the absence of a systemic energy source?
In summary, recent findings have moved central control of
bone remodeling and its relationship to energy status into the
forefront of skeletal and metabolic research. We can expect
even more provocative findings in the future, as new therapies
such as NMU antagonists are considered for targeting the cen-
tral regulatory circuits involved in bone remodeling.
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